Complete remission of third recurrence of acute myeloid leukemia after treatment with Imatinib (STI-571)

被引:11
|
作者
Schittenhelm, M
Aichele, O
Kröber, SM
Brümmendorf, T
Kanz, L
Denzlinger, C [1 ]
机构
[1] Univ Tubingen, Dept Haematol Oncol, Sch Med, D-72076 Tubingen, Germany
[2] Univ Tubingen, Inst Pathol, D-72076 Tubingen, Germany
关键词
AML; c-kit; CD117; Imatinib; glivec; STI-571;
D O I
10.1080/1042819031000077034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report the case of a 76-year old patient with third relapse of AML who was successfully treated with Imatinib. The decision to try Imatinib was guided by bright expression of c-kit on the patient's blasts. Treatment was well tolerated but the dose was reduced for pancytopenia and later stopped completely because of pneumonia. The patient recovered with i.v. antibiotics, antimycotics and s.c. G-CSF. Reevaluation of the bone marrow after the end of treatment demonstrated the absence of malignant blasts. Treatment with Imatinib was started again with the intention to prolong remission duration. During the following months peripheral blood counts stabilized in the normal range indicating that a fourth complete remission has been achieved in this patient. This is the first report demonstrating that Imatinib can induce complete remission in relapsed c-kit positive AML in an elderly patient. Prolonged cytopenia remains a considerable problem indicating that normal haematopoiesis is not completely independent of the signalling cascades inhibited by Imatinib. Nevertheless our report supports further study of this drug in c-kit positive AML.
引用
收藏
页码:1251 / 1253
页数:3
相关论文
共 50 条
  • [11] A phase II pilot study of Gleevec/Glivec (imatinib mesylate, STI-571) in patients with c-kit positive acute myeloid leukemia (AML).
    Fischer, T
    Beck, J
    Duyster, J
    Peschel, C
    Müller-Navia, J
    Jäger, E
    Knuth, A
    Gschaidmeier, H
    Huber, C
    BLOOD, 2002, 100 (11) : 561A - 561A
  • [12] Giant malignant gastrointestinal stromal tumors: Recurrence and effects of treatment with STI-571
    Chen, Teng-Wei
    Liu, Hsiao-Dung
    Shyu, Rong-Yaun
    Yu, Jyh-Cherng
    Shih, Ming-Lang
    Chang, Tzu-Ming
    Hsieh, Chung-Bao
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (02) : 260 - 263
  • [13] Giant malignant gastrointestinal stromal tumors: Recurrence and effects of treatment with STI-571
    Hsiao-Dung Liu
    Rong-Yaun Shyu
    Jyh-Cherng Yu
    Ming-Lang Shih
    Tzu-Ming Chang
    Chung-Bao Hsieh
    World Journal of Gastroenterology, 2005, (02) : 260 - 263
  • [14] Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation
    Olavarria, E
    Craddock, C
    Dazzi, F
    Marin, D
    Marktel, S
    Apperley, JF
    Goldman, JM
    BLOOD, 2002, 99 (10) : 3861 - 3862
  • [15] Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis
    Koh, LP
    Hwang, WYK
    Chuah, CTH
    Linn, YC
    Goh, YT
    Tan, CH
    Ng, HJ
    Tan, PHC
    BONE MARROW TRANSPLANTATION, 2003, 31 (04) : 305 - 308
  • [16] Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment
    Colombat, M
    Fort, MP
    Chollet, C
    Marit, G
    Roche, C
    Preudhomme, C
    Reiffers, J
    Praloran, V
    Mahon, FX
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (02): : 162 - 168
  • [17] Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis
    L P Koh
    W Y K Hwang
    C T H Chuah
    Y C Linn
    Y T Goh
    C H Tan
    H J Ng
    P H C Tan
    Bone Marrow Transplantation, 2003, 31 : 305 - 308
  • [18] Gleevec/Glivec (imatinib mesylate, STI-571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: Updated results of a phase II study.
    Sawyers, CL
    Hochhaus, A
    Feldman, E
    Goldman, JM
    Miller, C
    Ottman, OG
    Schiffer, CA
    Talpaz, M
    Guilhot, F
    Niederwieser, D
    Ben-Am, M
    Gathmann, I
    Ford, J
    Druker, BJ
    BLOOD, 2001, 98 (11) : 845A - 845A
  • [19] The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations
    Marin, D
    Marktel, S
    Bua, M
    Armstrong, L
    Goldman, JM
    Apperley, JF
    Olavarria, E
    HAEMATOLOGICA, 2002, 87 (09) : 979 - 988
  • [20] The clinical course of thrombocytopenia in patients treated with STI-571 (IMATINIB) for accelerated phase chronic myelogenous leukemia.
    van Deventer, HW
    Hall, MD
    Mitchell, BS
    Hogan, CM
    Lehman, MJ
    Bhagat, RK
    Berkowitz, LR
    Dunphy, CH
    Orlowski, RZ
    Stinchcombe, TE
    Smith, JS
    Powderly, JD
    Rao, KW
    Koehler, JA
    Nashed, A
    Shea, TC
    BLOOD, 2001, 98 (11) : 139A - 139A